**2-(3-fluoroanilino)-7-hydroxy-5-oxo-4H-thieno[3,2-b]pyridine-3-carbonitrile** is a complex organic molecule with a specific structure and chemical properties. It's likely a compound synthesized in a laboratory for research purposes, and its importance stems from its potential applications in various fields:
**Potential Applications:**
* **Pharmaceutical Research:** The molecule contains features commonly found in drugs. The presence of a thieno[3,2-b]pyridine core is often associated with biological activity, and the other functional groups (fluoroanilino, hydroxy, and cyano) could influence its interaction with biological targets. It might be a lead compound for developing new drugs for various conditions.
* **Materials Science:** Its complex structure and potential for functionalization could be beneficial in developing new materials with tailored properties.
* **Agricultural Chemistry:** The molecule might exhibit activity against pests or weeds. The presence of the thieno[3,2-b]pyridine core and other functional groups could contribute to its bioactivity.
* **Chemical Biology:** It can be used as a tool for studying biological processes. The molecule's structure can be modified to probe the mechanisms of enzyme activity, protein-protein interactions, or other biological processes.
**Importance for Research:**
* **Novelty and Potential:** The molecule represents a novel chemical entity with potential applications in different research areas.
* **Lead Compound Development:** If the molecule shows promising biological activity, it can serve as a lead compound for developing new drugs or agrochemicals.
* **Structure-Activity Relationship Studies:** By modifying the molecule's structure, researchers can explore the structure-activity relationships, which can lead to the design of more potent and selective compounds.
* **Understanding Biological Systems:** The molecule can be used as a probe to understand the mechanisms of biological processes and the interactions of chemicals with biological systems.
**Important Note:**
Without further context or information about its synthesis, biological activity, or intended application, it's impossible to provide a definitive answer about the specific importance of this molecule. The information provided above is based on the general characteristics and potential applications of similar compounds.
To gain a deeper understanding of its importance, more specific information regarding the molecule's properties and research context is required.
ID Source | ID |
---|---|
PubMed CID | 54676489 |
CHEMBL ID | 1509718 |
CHEBI ID | 120944 |
Synonym |
---|
HMS2644I07 |
MLS000663261 |
2-[(3-fluorophenyl)amino]-7-hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-3-carbonitrile |
smr000301292 |
CHEBI:120944 |
AKOS003678969 |
AKOS001756196 |
CHEMBL1509718 |
2-(3-fluoroanilino)-7-hydroxy-5-oxo-4h-thieno[3,2-b]pyridine-3-carbonitrile |
Q27209137 |
2-[(3-fluorophenyl)amino]-4,5-dihydro-7-hydroxy-5-oxothieno[3,2-b]pyridine-3-carbonitrile |
727685-40-7 |
DTXSID901122537 |
2-(3-fluoroanilino)-5,7-dihydroxythieno[3,2-b]pyridin-3-yl cyanide |
Class | Description |
---|---|
thienopyridine | Any organic heterobicyclic compound whose skeleton results from the formal ortho-fusion of any bond of a pyridine with any bond of a thiophene. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
USP1 protein, partial | Homo sapiens (human) | Potency | 2.2387 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 15.8489 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 89.1251 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 39.8107 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.6310 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 12.5893 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 65.2792 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
DNA polymerase beta | Homo sapiens (human) | Potency | 3.9811 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
snurportin-1 | Homo sapiens (human) | Potency | 65.2792 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 89.1251 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 18.3564 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 7.0795 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 28.1838 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 22.3872 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 0.8610 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |